- Conference Call and Webcast Today at 4:30 p.m. EST PASADENA, Calif. --(BUSINESS WIRE)--Nov. 25, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2019 . The company is hosting a conference call at 4:30 p.m.

- Company Expects to Initiate Phase 3 Clinical Trials Next Year PASADENA, Calif. --(BUSINESS WIRE)--Nov. 18, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented updated Phase 1 clinical data on its two RNAi-based cardiometabolic candidates, ARO-APOC3 targeting apolipoprotein C-III

PASADENA, Calif. --(BUSINESS WIRE)--Nov. 15, 2019-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that Bruce Given , M.D., Arrowhead’s chief operating officer and head of R&D, plans to retire on May 1, 2020 , after a more than 30 year career in biotechnology and pharmaceutical

PASADENA, Calif. --(BUSINESS WIRE)--Nov. 11, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 25, 2019 , at 4:30 p.m. EST to discuss its financial results for the fiscal year ended September 30, 2019 .

PASADENA, Calif. --(BUSINESS WIRE)--Nov. 8, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced Phase 2 clinical data on a double combination of JNJ-3989 (formerly ARO-HBV) and a nucleos(t)ide analog (NA), and the first clinical data on a triple combination of JNJ-3989, JNJ-6379,

PASADENA, Calif. --(BUSINESS WIRE)--Oct. 31, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented preclinical data at the 2019 North American Cystic Fibrosis Conference (NACFC) on ARO-ENaC, an inhaled RNAi therapeutic being developed as a potential treatment for cystic fibrosis

PASADENA, Calif. --(BUSINESS WIRE)--Oct. 18, 2019-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is hosting a Research & Development (R&D) Day today in New York to discuss its emerging pipeline of RNAi therapeutics that leverage its proprietary Targeted RNAi Molecule Platform (TRiM™) platform.

  PASADENA, Calif. --(BUSINESS WIRE)--Oct. 2, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development (R&D) Day to discuss its emerging pipeline of RNAi therapeutics that leverage its proprietary Targeted RNAi Molecule (TRIM TM ) platform from

  PASADENA, Calif. --(BUSINESS WIRE)--Sep. 30, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:   2019 Cantor Global Healthcare Conference   – New York , October 2-4, 2019     October 4 , 10:05 a.m.

PASADENA, Calif. --(BUSINESS WIRE)--Sep. 20, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on September 13, 2019 , the Compensation Committee of the Board of Directors approved "inducement" grants to 17 new